|
1
|
Vargas-Hernández VM, Moreno-Eutimio MA,
Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent
epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Imai S, Armstrong CM, Kaeberlein M and
Guarente L: Transcriptional silencing and longevity protein Sir2 is
an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dan L, Klimenkova O, Klimiankou M, Klusman
JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K and Skokowa J:
The role of sirtuin 2 activation by nicotinamide
phosphoribosyltransferase in the aberrant proliferation and
survival of myeloid leukemia cells. Haematologica. 97:551–559.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilson JM, Le VQ, Zimmerman C, Marmorstein
R and Pillus L: Nuclear export modulates the cytoplasmic Sir2
homologue Hst2. EMBO Rep. 7:1247–1251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cha YI and Kim HS: Emerging role of
sirtuins on tumorigenesis: Possible link between aging and cancer.
BMB Rep. 46:429–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Dai D, Lu Q, Fei M, Li M and Wu X:
Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21
axis. Biochem Biophys Res Commun. 441:661–667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karwaciak I, Gorzkiewicz M, Ryba K,
Dastych J, Pulaski L and Ratajewski M: AC-93253 triggers the
downregulation of melanoma progression markers and the inhibition
of melanoma cell proliferation. Chem Biol Interact. 236:9–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Chan AW, To KF, Chen W, Zhang Z,
Ren J, Song C, Cheung YS, Lai PB, Cheng SH, et al: SIRT2
overexpression in hepatocellular carcinoma mediates epithelial to
mesenchymal transition by protein kinase B/glycogen synthase
kinase-3β/β-catenin signaling. Hepatology. 57:2287–2298. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pizarro JG, Folch J, Esparza JL, Jordan J,
Pallàs M and Camins A: A molecular study of pathways involved in
the inhibition of cell proliferation in neuroblastoma B65 cells by
the GSK-3 inhibitors lithium and SB-415286. J Cell Mol Med.
13:3906–3917. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang
P, Xu YH, Dong B, Xiong Y, Lei QY and Guan KL: Lysine-5 acetylation
negatively regulates lactate dehydrogenase A and is decreased in
pancreatic cancer. Cancer Cell. 23:464–476. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hiratsuka M, Inoue T, Toda T, Kimura N,
Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa
A and Oshimura M: Proteomics-based identification of differentially
expressed genes in human gliomas: Down-regulation of SIRT2 gene.
Biochem Biophys Res Commun. 309:558–566. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peters CJ, Rees JR, Hardwick RH, Hardwick
JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, et
al: A 4-gene signature predicts survival of patients with resected
adenocarcinoma of the esophagus, junction and gastric cardia.
Gastroenterology. 139:1995–2004.e15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lennerz V, Fatho M, Gentilini C, Frye RA,
Lifke A, Ferel D, Wölfel C, Huber C and Wölfel T: The response of
autologous T cells to a human melanoma is dominated by mutated
neoantigens. Proc Natl Acad Sci USA. 102:16013–16018. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Xie QR, Chen Z, Lu S and Xia W:
Regulation of SIRT2 levels for human non-small cell lung cancer
therapy. Lung Cancer. 82:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu W, Jiang K, Shen M, Qian Y and Peng Y:
SIRT2 suppresses non-small cell lung cancer growth by targeting
JMJD2A. Biol Chem. 396:929–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mangas-Sanjuan V, Oláh J, Gonzalez-Alvarez
I, Lehotzky A, Tőkési N, Bermejo M and Ovádi J: Tubulin acetylation
promoting potency and absorption efficacy of deacetylase
inhibitors. Br J Pharmacol. 172:829–840. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang F, Chan CH, Chen K, Guan X, Lin HK
and Tong Q: Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to
Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene.
31:1546–1557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoffmann G, Breitenbücher F, Schuler M and
Ehrenhofer-Murray AE: A novel sirtuin 2 (SIRT2) inhibitor with
p53-dependent pro-apoptotic activity in non-small cell lung cancer.
J Biol Chem. 289:5208–5216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim HS, Vassilopoulos A, Wang RH, Lahusen
T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2
maintains genome integrity and suppresses tumorigenesis through
regulating APC/C activity. Cancer Cell. 20:487–499. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang W, Wang S, Xiao M, Lin Y, Zhou L,
Lei Q, Xiong Y, Guan KL and Zhao S: Acetylation regulates
gluconeogenesis by promoting PEPCK1 degradation via recruiting the
UBR5 ubiquitin ligase. Mol Cell. 43:33–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tobin NP, Foukakis T, De Petris L and
Bergh J: The importance of molecular markers for diagnosis and
selection of targeted treatments in patients with cancer. J Intern
Med. 278:545–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu J, Zhang YC, Suo WH, Liu XB, Shen WW,
Tian H and Fu GH: Induction of anion exchanger-1 translation and
its opposite roles in the carcinogenesis of gastric cancer cells
and differentiation of K562 cells. Oncogene. 29:1987–1996. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui Y, Li SB, Peng XC, Wu J and Fu GH:
Trastuzumab inhibits growth of HER2-negative gastric cancer cells
through gastrin-initialized CCKBR signaling. Dig Dis Sci.
60:3631–3641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu PY, Xu N, Malyukova A, Scarlett CJ,
Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, et al: The
histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death
Differ. 20:503–514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin R, Tao R, Gao X, Li T, Zhou X, Guan
KL, Xiong Y and Lei QY: Acetylation stabilizes ATP-citrate lyase to
promote lipid biosynthesis and tumor growth. Mol Cell. 51:506–518.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dickson MA: Molecular pathways: CDK4
inhibitors for cancer therapy. Clin Cancer Res. 20:3379–3383. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nezhat FR, Apostol R, Nezhat C and Pejovic
T: New insights in the pathophysiology of ovarian cancer and
implications for screening and prevention. Am J Obstet Gynecol.
213:262–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zapardiel I, Diestro MD and Aletti G:
Conservative treatment of early stage ovarian cancer: Oncological
and fertility outcomes. Eur J Surg Oncol. 40:387–393. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jackson AL, Eisenhauer EL and Herzog TJ:
Emerging therapies: Angiogenesis inhibitors for ovarian cancer.
Expert Opin Emerg Drugs. 20:331–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rutten MJ, Boldingh JH, Schuit E, Trum H,
van Driel W, Mol BW, Kenter GG and Buist MR: Development and
internal validation of a prognostic model for survival after
debulking surgery for epithelial ovarian cancer. Gynecol Oncol.
135:13–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pandithage R, Lilischkis R, Harting K,
Wolf A, Jedamzik B, Lüscher-Firzlaff J, Vervoorts J, Lasonder E,
Kremmer E, Knöll B and Lüscher B: The regulation of SIRT2 function
by cyclin-dependent kinases affects cell motility. J Cell Biol.
180:915–929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sui L, Dong Y, Ohno M, Goto M, Inohara T,
Sugimoto K, Tai Y, Hando T and Tokuda M: Inverse expression of Cdk4
and p16 in epithelial ovarian tumors. Gynecol Oncol. 79:230–237.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang H, Goode T, Iakova P, Albrecht JH and
Timchenko NA: C/EBPalpha triggers proteasome-dependent degradation
of cdk4 during growth arrest. EMBO J. 21:930–941. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ortega S, Malumbres M and Barbacid M:
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim
Biophys Acta. 1602:73–87. 2002.PubMed/NCBI
|
